Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Brachytherapy
100%
Prostate Carcinoma
100%
Prostascint
100%
Prostate
40%
Computed Tomography
20%
Novel Technique
20%
Prostate Cancer
20%
Treatment Outcome
20%
Dose Escalation
20%
Prostate-specific Antigen
20%
Metastatic Disease
20%
Recurrent Disease
20%
U.S. Food
20%
Prostate-specific Antigen Level
20%
Clinical High Risk
20%
Treatment Verification
20%
Membrane Glycoproteins
20%
Tissue Structure
20%
Rising Prostate-specific Antigen
20%
Radiotherapeutics
20%
Treatment Morbidity
20%
Capromab Pendetide
20%
Post-prostatectomy
20%
Medicine and Dentistry
Brachytherapy
100%
Prostate Adenocarcinoma
100%
Capromab Pendetide in 111
100%
Malignant Neoplasm
16%
Pelvis
16%
Metastatic Carcinoma
16%
Computer Assisted Tomography
16%
Prostate Cancer
16%
Recurrent Disease
16%
Antibodies
16%
Prostate Specific Antigen
16%
Prostatectomy
16%
Glycoprotein
16%
Tissue Structure
16%
Indium 111
16%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Adenocarcinoma
100%
Malignant Neoplasm
16%
Metastasis
16%
Prostate Cancer
16%
Glycoprotein
16%
Prostate Specific Antigen
16%
Recurrent Disease
16%
Antibodies
16%
Blood Group A Antigen
16%
Indium 111
16%
Immunology and Microbiology
Capromab Pendetide in 111
100%
Prostate Specific Membrane Antigen
16%